CONMED CORPORATION (CNMD) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
45/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCNMD / S&P -7.44% / 15.20% |
LoseCNMD / S&P CNMD unavailable / 15.00% |
LoseCNMD / S&P CNMD unavailable / 50.40% |
| 2026-Q10/3 |
LoseCNMD / S&P -12.91% / -4.33% |
LoseCNMD / S&P CNMD unavailable / 11.30% |
LoseCNMD / S&P CNMD unavailable / 27.70% |
| 2025-Q40/3 |
LoseCNMD / S&P -13.67% / 2.65% |
LoseCNMD / S&P 5.18% / 9.00% |
LoseCNMD / S&P -64.39% / 13.40% |
| 2025-Q31/3 |
LoseCNMD / S&P -9.35% / 8.12% |
WinCNMD / S&P 4.61% / 4.61% |
LoseCNMD / S&P -51.31% / 13.45% |
| 2025-Q21/3 |
LoseCNMD / S&P -13.45% / 10.94% |
LoseCNMD / S&P 3.94% / 4.83% |
WinCNMD / S&P 12.42% / 10.63% |
| 2025-Q11/3 |
LoseCNMD / S&P -11.46% / -4.27% |
LoseCNMD / S&P 4.32% / 4.98% |
WinCNMD / S&P 45.59% / 10.57% |
| 2024-Q41/3 |
LoseCNMD / S&P -4.57% / 2.41% |
LoseCNMD / S&P 5.00% / 5.25% |
WinCNMD / S&P 107.84% / 6.15% |
| 2024-Q32/3 |
LoseCNMD / S&P 4.03% / 5.89% |
WinCNMD / S&P 10.23% / 5.89% |
WinCNMD / S&P 121.58% / 6.11% |
| 2024-Q22/3 |
LoseCNMD / S&P -13.20% / 4.28% |
WinCNMD / S&P 12.02% / 5.38% |
WinCNMD / S&P 9.03% / 5.12% |
| 2024-Q11/3 |
LoseCNMD / S&P -26.70% / 10.56% |
WinCNMD / S&P 14.83% / 5.71% |
LoseCNMD / S&P -181.56% / 5.59% |
| 2023-Q41/3 |
LoseCNMD / S&P 8.78% / 11.69% |
WinCNMD / S&P 19.06% / 6.81% |
LoseCNMD / S&P -173.12% / 7.78% |
| 2023-Q31/3 |
LoseCNMD / S&P -25.65% / -3.27% |
WinCNMD / S&P 9.36% / 7.52% |
LoseCNMD / S&P -164.41% / -5.03% |
| 2023-Q21/3 |
WinCNMD / S&P 31.04% / 8.74% |
LoseCNMD / S&P 9.28% / 9.50% |
LoseCNMD / S&P -172.73% / -8.57% |
| 2023-Q11/3 |
WinCNMD / S&P 17.43% / 7.50% |
LoseCNMD / S&P 7.68% / 10.77% |
LoseCNMD / S&P -252.38% / -15.69% |
| 2022-Q41/3 |
WinCNMD / S&P 10.80% / 7.56% |
LoseCNMD / S&P 3.45% / 11.88% |
LoseCNMD / S&P -243.81% / -17.99% |
| 2022-Q30/3 |
LoseCNMD / S&P -16.10% / -4.88% |
LoseCNMD / S&P 7.99% / 13.47% |
LoseCNMD / S&P -246.04% / -1.41% |
| 2022-Q20/3 |
LoseCNMD / S&P -35.40% / -16.10% |
LoseCNMD / S&P 6.52% / 13.71% |
LoseCNMD / S&P -322.47% / 11.04% |
| 2022-Q12/3 |
WinCNMD / S&P 4.94% / -4.60% |
LoseCNMD / S&P 15.79% / 15.97% |
WinCNMD / S&P 412.20% / 42.23% |
| 2021-Q42/3 |
LoseCNMD / S&P 8.51% / 11.03% |
WinCNMD / S&P 17.18% / 15.00% |
WinCNMD / S&P 546.67% / 96.40% |
| 2021-Q31/3 |
LoseCNMD / S&P -4.65% / 0.58% |
WinCNMD / S&P 13.15% / 10.77% |
LoseCNMD / S&P -6833.33% / 69.42% |
| 2021-Q21/3 |
LoseCNMD / S&P 5.39% / 8.55% |
WinCNMD / S&P 12.44% / 6.58% |
LoseCNMD / S&P -6033.33% / 51.81% |
| 2021-Q11/3 |
WinCNMD / S&P 16.79% / 6.17% |
LoseCNMD / S&P -7.32% / -1.06% |
LoseCNMD / S&P -63.39% / 7.39% |
| 2020-Q41/3 |
WinCNMD / S&P 42.64% / 12.15% |
LoseCNMD / S&P -9.70% / -3.72% |
LoseCNMD / S&P -68.75% / -33.42% |
| 2020-Q31/3 |
WinCNMD / S&P 9.53% / 8.93% |
LoseCNMD / S&P -6.24% / -2.04% |
LoseCNMD / S&P -103.00% / -27.10% |
| 2020-Q21/3 |
WinCNMD / S&P 26.06% / 20.54% |
LoseCNMD / S&P -3.45% / -0.46% |
LoseCNMD / S&P -103.09% / -27.11% |
| 2020-Q12/3 |
LoseCNMD / S&P -48.64% / -19.60% |
WinCNMD / S&P 8.54% / 3.47% |
WinCNMD / S&P 3.70% / -14.75% |
| 2019-Q42/3 |
WinCNMD / S&P 16.52% / 9.07% |
WinCNMD / S&P 11.10% / 5.36% |
LoseCNMD / S&P -31.91% / 2.99% |
| 2019-Q32/3 |
WinCNMD / S&P 12.59% / 1.70% |
WinCNMD / S&P 11.07% / 5.02% |
LoseCNMD / S&P -60.47% / 0.21% |
| 2019-Q21/3 |
LoseCNMD / S&P 3.12% / 4.30% |
WinCNMD / S&P 8.92% / 6.64% |
LoseCNMD / S&P -62.55% / 8.65% |
| 2019-Q11/3 |
WinCNMD / S&P 29.89% / 13.65% |
LoseCNMD / S&P 7.89% / 8.12% |
LoseCNMD / S&P -56.97% / 14.29% |
| 2018-Q40/3 |
LoseCNMD / S&P -18.72% / -13.52% |
LoseCNMD / S&P 7.94% / 9.05% |
LoseCNMD / S&P -28.79% / 18.23% |
| 2018-Q32/3 |
WinCNMD / S&P 8.50% / 7.71% |
LoseCNMD / S&P 7.95% / 10.21% |
WinCNMD / S&P 351.79% / 19.06% |
| 2018-Q22/3 |
WinCNMD / S&P 15.90% / 3.43% |
LoseCNMD / S&P 7.11% / 9.03% |
WinCNMD / S&P 362.50% / 14.46% |
| 2018-Q12/3 |
WinCNMD / S&P 24.64% / -0.76% |
LoseCNMD / S&P 5.59% / 7.68% |
WinCNMD / S&P 470.45% / 12.46% |
| 2017-Q41/3 |
LoseCNMD / S&P -2.48% / 6.64% |
LoseCNMD / S&P 4.31% / 7.03% |
WinCNMD / S&P 280.77% / 13.82% |
| 2017-Q30/3 |
LoseCNMD / S&P 3.41% / 4.48% |
LoseCNMD / S&P 3.66% / 5.68% |
LoseCNMD / S&P 0.00% / 17.57% |
| 2017-Q22/3 |
WinCNMD / S&P 15.14% / 3.09% |
WinCNMD / S&P 5.14% / 4.83% |
LoseCNMD / S&P -9.68% / 17.74% |
| 2017-Q11/3 |
LoseCNMD / S&P 1.05% / 6.07% |
WinCNMD / S&P 6.43% / 3.67% |
LoseCNMD / S&P -44.30% / 13.32% |
| 2016-Q42/3 |
WinCNMD / S&P 10.74% / 3.82% |
WinCNMD / S&P 6.17% / 2.09% |
LoseCNMD / S&P -52.73% / 7.05% |
| 2016-Q31/3 |
LoseCNMD / S&P -15.65% / 3.85% |
WinCNMD / S&P 3.77% / 0.20% |
LoseCNMD / S&P -54.47% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CNMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -7.08% | 20.78% |
| Annualized return | -7.08% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CNMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -59.41% | 83.14% |
| Annualized return | -16.50% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CNMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 36.95% | 319.30% |
| Annualized return | 3.19% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |